Success in Treating Dry Age-Related Macular Degeneration with AREDS 2
Literature Review
DOI:
https://doi.org/10.55175/cdk.v53i09.2127Keywords:
Age-related macular degeneration, Age-Related Eye Disease Study 2, AMD, AREDS2, dry AMD, wet AMDAbstract
Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss. Recent 5-year follow-up findings confirm that AREDS2 formula (vitamins C and E, lutein, zeaxanthin, zinc, copper) significantly reduces the risk of progression from intermediate to advanced AMD. New analyses suggest AREDS2 supplements may slow geographic atrophy (GA) expansion towards the fovea in late-stage dry AMD, potentially preserving central vision. The supplement is recommended for patients with intermediate or advanced AMD, not in early stages. The AREDS2 formula does not prevent the onset of AMD or restore vision that has already been lost. Its main role is to reduce the risk of disease progression in appropriately selected patients. Lutein and zeaxanthin are preferred to β-carotene because β-carotene increases the risk of lung cancer, particularly among current and former smokers. Long-term use should be based on the AMD stage, smoking history, comorbidities, and potential interactions with other medications. Regular ophthalmological monitoring remains necessary to assess disease progression and detect conversion to neovascular AMD.
Downloads
References
Tenchov R, Sasso JM, Wang X, Zhou QA. Aging hallmarks and progression and age-related diseases: a landscape view of research advancement. ACS Chem Neurosci. 2024;15(1):1–30. doi: 10.1021/acschemneuro.3c00531.
InformedHealth.org. Overview: age-related macular degeneration (AMD) [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK315804/.
Chaudhuri M, Hassan Y, Bakka Vemana PPS, Bellary Pattanashetty MS, Abdin ZU, Siddiqui HF. Age-related macular degeneration: an exponentially emerging imminent threat of visual impairment and irreversible blindness. Cureus. 2023;15(5):e39624. doi: 10.7759/cureus.39624.
PERDAMI. Pedoman penatalaksanaan age-related macular degeneration (AMD) di Indonesia. Jakarta: Perhimpunan Dokter Spesialis Mata Indonesia (PERDAMI); 2022. p. 2–102.
Vyawahare H, Shinde P. Age-related macular degeneration: epidemiology, pathophysiology, diagnosis, and treatment. Cureus. 2022;14(9):e29583. doi: 10.7759/cureus.29583.
Chew EY, Clemons T, SanGiovanni JP, Danis R, Domalpally A, McBee W, et al. The Age-related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS 2 report number 1). Ophthalmology. 2012;119(11):2282–9. doi: 10.1016/j.ophtha.2012.05.027.
Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database Syst Rev. 2023;9(9):CD000254. doi: 10.1002/14651858.CD000254.pub5.
Ruia S, Kaufman EJ. Macular degeneration [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560778/. PMID: 32809613.
Flaxel CJ, Adelman RA, Bailey ST, Fawzi A, Lim JI, Vemulakonda GA, et al. Age-related macular degeneration preferred practice pattern®. Ophthalmology. 2020;127(1):P1–65. doi: 10.1016/j.ophtha.2019.09.024.
Ruan Y, Jiang S, Gericke A. Age-related macular degeneration: role of oxidative stress and blood vessels. Int J Mol Sci. 2021;22(3):1296. doi:10.3390/ijms22031296.
Fleckenstein M, Keenan TDL, Guymer RH, Chakravarthy U, Schmitz-Valckenberg S, Klaver CC, et al. Age-related macular degeneration. Nat Rev Dis Primers. 2021;7(1):31. doi: 10.1038/s41572-021-00265-2.
Khan JC, Thurlby DA, Shahid H, Clayton DG, Yates JRW, Bradley M, et al. Smoking and age-related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation. Br J Ophthalmol. 2006;90(1):75–80. doi: 10.1136/bjo.2005.073643.
Clemons TE, Milton RC, Klein R, Seddon JM, Ferris FL, Age-Related Eye Disease Study Research Group. Risk factors for the incidence of advanced age-related macular degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. Ophthalmology. 2005;112(4):533–9. doi: 10.1016/j.ophtha.2004.10.047.
SanGiovanni JP, Agron E, Meleth AD, Reed GF, Sperduto RD, Clemons TE, et al. ω–3 long-chain polyunsaturated fatty acid intake and 12-y incidence of neovascular age-related macular degeneration and central geographic atrophy: AREDS report 30, a prospective cohort study from the Age-Related Eye Disease Study. Am J Clin Nutr. 2009;90(6):1601–7. doi: 10.3945/ajcn.2009.27594.
Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308(5720):385–9. doi: 10.1126/science.1109557.
Yates JRW, Sepp T, Matharu BK, Khan JC, Thurlby DA, Shahid H, et al. Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med. 2007;357(6):553–61. doi: 10.1056/NEJMoa072618.
Fraser-Bell S, Choudhury F, Klein R, Azen S, Varma R. Ocular risk factors for age-related macular degeneration: the Los Angeles Latino eye study. Am J Ophthalmol. 2010;149(5):735–40. doi: 10.1016/j.ajo.2009.11.013.
Berber P, Grassmann F, Kiel C, Weber BHF. An eye on age-related macular degeneration: the role of microRNAs in disease pathology. Mol Diagn Ther. 2017;21(1):31–43. doi: 10.1007/s40291-016-0234-z.
Fisher CR, Ferrington DA. Perspective on AMD pathobiology: a bioenergetic crisis in the RPE. Investig Opthalmology Vis Sci. 2018;59(4):AMD41. doi: 10.1167/iovs.18-24289.
Qin S, Dong N, Yang M, Wang J, Feng X, Wang Y. Complement inhibitors in age-related macular degeneration: a potential therapeutic option. J Immunol Res. 2021;2021:1–15. doi: 10.1155/2021/9945725.
von der Emde L, Pfau M, Holz FG, Fleckenstein M, Kortuem K, Keane PA, et al. AI-based structure-function correlation in age-related macular degeneration. Eye (Lond). 2021;35(8):2110–8. doi: 10.1038/s41433-021-01503-3.
Jabbehdari S, Handa JT. Oxidative stress as a therapeutic target for the prevention and treatment of early age-related macular degeneration. Surv Ophthalmol. 2021;66(3):423–40. doi: 10.1016/j.survophthal.2020.09.002.
Curcio CA. Photoreceptor topography in ageing and age-related maculopathy. Eye 2001;15(3):376–83. doi: 10.1038/eye.2001.140.
Westphal D, Kluck RM, Dewson G. Building blocks of the apoptotic pore: how Bax and Bak are activated and oligomerize during apoptosis. Cell Death Differ. 2014;21(2):196–205. doi: 10.1038/cdd.2013.139.
Apte RS. Regulation of angiogenesis by macrophages. Adv Exp Med Biol. 2010;15(9):664. doi: 10.1007/978-1-4419-1399-9_2.
Iliescu DA, Ghita AC, Ilie LA, Voiculescu SE, Geamanu A, Ghita AM. Non-neovascular age-related macular degeneration assessment: focus on optical coherence tomography biomarkers. Diagnostics (Basel). 2024;14(7):764. doi: 10.3390/diagnostics14070764.
Pugazhendhi A, Hubbell M, Jairam P, Ambati B. Neovascular macular degeneration: a review of etiology, risk factors, and recent advances in research and therapy. Int J Mol Sci. 2021;22(3):1170. doi: 10.3390/ijms22031170.
Deng Y, Qiao L, Du M, Qu C, Wan L, Li J, et al. Age-related macular degeneration: epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy. Genes Dis. 2022;9(1):62–79. doi: 10.1016/j.gendis.2021.02.009.
Vemulakonda GA, Bailey ST, Kim SJ, Kovach JL, Lim JI, Ying GS, et al. Age-related macular degeneration preferred practice pattern®. Ophthalmology 2025;132(4):P1–74. doi: 10.1016/j.ophtha.2024.12.018.
Al-Khersan H, Hussain RM, Ciulla TA, Dugel PU. Innovative therapies for neovascular age-related macular degeneration. Expert Opin Pharmacother. 2019;20(15):1879–91. doi: 10.1080/14656566.2019.1636031
Sharma A, Kumar N, Parachuri N, Bandello F, Kuppermann BD, Loewenstein A. Ranibizumab biosimilar (razumab) vs innovator ranibizumab (lucentis) in neovascular age-related macular degeneration (n-AMD)- efficacy and safety (BIRA study). Eye (Lond). 2022;36(5):1106–7. doi:10.1038/s41433-021-01616-9.
Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins c and e, beta carotene, and zinc for age-related macular degeneration and vision loss. Arch Ophthalmol. 2001;119(10):1417–36. doi:10.1001/archopht.119.10.1417.
Cabral de Guimaraes TA, Daich Varela M, Georgiou M, Michaelides M. Treatments for dry age-related macular degeneration: therapeutic avenues, clinical trials and future directions. Br J Ophthalmol. 2022;106(3):297–304. doi: 10.1136/bjophthalmol-2020-318452
Yang B, Li G, Liu J, Li X, Zhang S, Sun F, et al. Nanotechnology for age-related macular degeneration. Pharmaceutics. 2021;13(12):2035. doi:10.3390/pharmaceutics13122035.
Chew EY, Clemons TE, Keenan TDL, Agron E, Malley CE, Dolmalpally A. The results of the 10-year follow-on study of the Age-Related Eye Disease Study 2 (AREDS2). IOVS. 2021;62(8):1215.
Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA. 2013;309(19):2005–15. doi: 10.1001/jama.2013.4997.
Lima VC, Rosen RB, Farah M. Macular pigment in retinal health and disease. Int J Retin Vitr. 2016;2:19. doi: 10.1186/s40942-016-0044-9.
Liu Y, Ni M, Wu R, Yang Z, Zhu X, Chen J. The level and efficacy of lutein in patients with age-related macular degeneration: a comprehensive systematic review and meta-analysis. Ann Transl Med. 2022;10(6):299. doi: 10.21037/atm-22-173.
Chew EY, Clemons TE, Agron E, Domalpally A, Keenan TDL, Vitale S, et al. Long-term outcomes of adding lutein/zeaxanthin and ω-3 fatty acids to the AREDS supplements on age-related macular degeneration progression. JAMA Ophthalmol. 2022;140(7):692–8. doi: 10.1001/jamaophthalmol.2022.1640.
Tram NK, McLean RM, Swindle-Reilly KE. Glutathione improves the antioxidant activity of vitamin c in human lens and retinal epithelial cells: implications for vitreous substitutes. Curr Eye Res. 2021;46(4):470–81. doi: 10.1080/02713683.2020.1809002.
Rozanowska MB, Czuba-Pelech B, Rozanowski B. Is there an optimal combination of AREDS2 antioxidants zeaxanthin, vitamin e and vitamin c on light-induced toxicity of vitamin a aldehyde to the retina? Antioxidants. 2022;11(6):1132. doi: 10.3390/antiox11061132.
Skowronska-Krawczyk D, Chao DL. Long-chain polyunsaturated fatty acids and age-related macular degeneration. Adv Exp Med Biol. 2019;1185:39–43. doi: 10.1007/978-3-030-27378-1_7.
Edwards G, Olson CG, Euritt CP, Koulen P. Molecular mechanisms underlying the therapeutic role of vitamin e in age-related macular degeneration. Front Neurosci. 2022;16:890021. doi: 10.3389/fnins.2022.890021.
Erie JC, Good JA, Butz JA, Pulido JS. Reduced zinc and copper in the retinal pigment epithelium and choroid in age-related macular degeneration. Am J Ophthalmol. 2009;147(2):276–82.e1. doi: 10.1016/j.ajo.2008.08.014.
Galindo-Camacho RM, Blanco-Llamero C, da Ana R, Fuertes MA, Senorans FJ, Silva AM, et al. Therapeutic approaches for age-related macular degeneration. Int J Mol Sci. 2022;23(19):11769. doi: 10.3390/ijms231911769.
Kaarniranta K, Blasiak J, Liton P, Boulton M, Klionsky DJ, Sinha D. Autophagy in age-related macular degeneration. Autophagy. 2023;19(2):388–400. doi: 10.1080/15548627.2022.2069437.
Mrowicka M, Mrowicki J, Kucharska E, Majsterek I. Lutein and zeaxanthin and their roles in age-related macular degeneration-neurodegenerative disease. Nutrients. 2022;14(4):827. doi: 10.3390/nu14040827.
Roberts JE, Dennison J. The photobiology of lutein and zeaxanthin in the eye. J Ophthalmol. 2015;2015:687173. doi: 10.1155/2015/687173.
Gorusupudi A, Nelson K, Bernstein PS. The Age-Related Eye Disease 2 Study: micronutrients in the treatment of macular degeneration. Adv Nutr. 2017;8(1):40–53. doi: 10.3945/an.116.013177.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Ni Putu Dian Apriandary
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
